Story perspectives

FDA Recalls Xanax XR Over Efficacy Concerns

4/21/2026

Summary

Story summary

The U.S. Food and Drug Administration announced a voluntary recall of a single Viatris-distributed Xanax XR 3 mg extended-release tablet lot after dissolution issues could reduce efficacy.
Viatris initiated the recall on March 17, 2026, after internal testing identified the dissolution defect.
This is not Xanax XR’s first recall, with related problems in 2012 and 2022.
No injuries have been reported, but the recall raises concerns about trust in anxiety medicines.

1 of 1

Story summary

The U.S. Food and Drug Administration announced a voluntary recall of a single Viatris-distributed Xanax XR 3 mg extended-release tablet lot after dissolution issues could reduce efficacy.
Viatris initiated the recall on March 17, 2026, after internal testing identified the dissolution defect.
This is not Xanax XR’s first recall, with related problems in 2012 and 2022.
No injuries have been reported, but the recall raises concerns about trust in anxiety medicines.